Causes and diagnosis of copper deficiency [2]

American Journal of Hematology

Volumn 83, Issue 1, 2008, Pages 87-88

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER; TETRATHIOMOLYBDIC ACID; ZINC;

ANGIOGENESIS; AUTOIMMUNE DISEASE; CIRCULATION; COPPER DEFICIENCY; COPPER METABOLISM; DIAGNOSTIC PROCEDURE; EXPERIMENTAL STUDY; FIBROSIS; INFLAMMATION; LETTER; MEDICAL LITERATURE; MYELODYSPLASIA; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

COPPER; HEMOPHILIA B; HUMANS; MUTATION;

EID: 38349070798     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21050     Document Type: Letter

References (6)

1. Huff JD, Keung YK, Thakuri M, et al. Copper deficiency causes reversible myelodysplasia. Am J Hematol. 2007;82:625-630.
2. Hedera P, Fink JK, Bockenstedt PL, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown source: Further support for existence of a new zinc overload syndrome. Arch of Neurol 2003;60:1303-1306.
3. Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis, and inflammation. J Cell Mol Med 2003;7:11-20.
4. Brewer GJ. Copper lowering therapy with tetrathiomolybdate produces antiangiogenic, anticancer, antifibrotic and antiinflammatory effects. Semin Integr Med 2003;1:181-190.
5. Brewer GJ. Copper in medicine. Curr Opin Chem Biol 2003;7:207-212.
6. Brewer GJ, Dick R, Zeng C, Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 2006;100(5/6):927-930.